Did Amy Schumer confirm she used Mounjaro?

Yes. Schumer publicly confirmed in 2023 via Instagram and podcast interviews that she tried Mounjaro (tirzepatide) for postpartum weight loss and subsequently discontinued it due to side effects.

Why did Amy Schumer stop taking Mounjaro?

Schumer described the side effects as intolerable. She did not specify exact symptoms in detail, but her descriptions were consistent with the gastrointestinal effects (nausea, vomiting, GI discomfort) that are the most common adverse events reported in tirzepatide clinical trials.

Is it common to stop GLP-1 medications due to side effects?

In clinical trials of tirzepatide, 4% to 7% of participants discontinued due to adverse events, primarily gastrointestinal. Real-world discontinuation rates tend to be higher, with some analyses suggesting 30% to 50% of patients stop within the first year for various reasons including side effects, cost, and access.

Can you switch from Mounjaro to another GLP-1 if you can't tolerate it?

Yes. Semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda) have different receptor profiles than tirzepatide. Patients who are intolerant to one GLP-1-class medication may tolerate another. This should be discussed with a prescriber rather than attempted independently.

The Medical Takeaways from Amy Schumer's GLP-1 Story

Q: What happens to weight after stopping a GLP-1 agonist?

The SURMOUNT-4 trial showed that patients who stopped tirzepatide after 36 weeks regained roughly two-thirds of their lost weight over the following year. Appetite, metabolic markers, and body composition trends all partially reverted toward baseline.

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Celebrity: Amy Schumer
Drug: Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist
Status: Confirmed use, confirmed discontinuation
Public disclosure: 2023 Instagram posts and podcast interviews
Reason for stopping: Self-reported intolerable side effects
Key clinical angle: What GLP-1 discontinuation looks like, and why dose titration matters

What Amy Schumer Actually Said

In 2023, Schumer posted on Instagram about her experience with Mounjaro, confirming she had tried the medication as part of her effort to lose weight gained during and after pregnancy. She described the side effects as severe enough that she chose to stop. In subsequent podcast appearances, she elaborated: the gastrointestinal symptoms made daily life difficult, and the medication was not worth continuing at the dose she had reached.

This was not a vague celebrity admission. Schumer named the drug, described the side effects in plain language, and was clear that she stopped. That level of specificity makes her public record unusually useful for clinical discussion.

She did not disclose her exact dose, how long she titrated, or whether her prescriber attempted dose adjustments before she discontinued. Those details matter clinically, and their absence is worth noting.

Mounjaro: The Drug Behind the Story

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist approved by the FDA in 2022 for type 2 diabetes and later for chronic weight management under the brand name Zepbound. It works by mimicking two incretin hormones, slowing gastric emptying, reducing appetite through central nervous system signaling, and improving insulin sensitivity.

Tirzepatide is administered as a once-weekly subcutaneous injection. The approved titration schedule starts at 2.5 mg weekly for four weeks, then increases to 5 mg. From there, the dose can be raised in 2.5 mg increments every four weeks, up to a maximum of 15 mg weekly.

In the SURMOUNT-1 trial, participants on the highest dose (15 mg) lost an average of 22.5% of body weight over 72 weeks. The 5 mg group lost approximately 15%. Those numbers are population averages. Individual responses vary substantially based on baseline BMI, metabolic profile, adherence, and genetic factors affecting GLP-1 receptor sensitivity.

The Side-Effect Profile Schumer Described

Schumer's public comments focused on gastrointestinal side effects. This aligns with the most common adverse events reported in clinical trials of tirzepatide. In SURMOUNT-1, the rates were:

Nausea: 24% to 33% (dose-dependent)
Diarrhea: 18% to 23%
Vomiting: 6% to 13%
Constipation: 13% to 17%
Decreased appetite: reported but often considered the therapeutic effect itself

These rates are highest during dose escalation periods. Most trial participants who experienced GI symptoms saw them diminish after 4 to 8 weeks at a stable dose. But "most" is not "all." A meaningful minority of patients, roughly 4% to 7% in SURMOUNT-1, discontinued tirzepatide due to adverse events.

The HealthRX Medical Team notes that Schumer's experience falls squarely within the documented discontinuation rate. She is not an outlier. She represents the subset of patients for whom the standard titration schedule produces symptoms that outweigh the benefit.

Why Some Patients Cannot Tolerate GLP-1 Agonists

GLP-1 receptor agonists slow gastric emptying. That is part of the mechanism. For some patients, this effect is too pronounced, producing persistent nausea, early satiety that tips into discomfort, or vomiting that disrupts daily function.

Several factors influence individual tolerability:

Gastric motility baseline. Patients with pre-existing gastroparesis or slow gastric emptying are at higher risk for severe GI symptoms. This is not always diagnosed before GLP-1 initiation.

Titration speed. The FDA-approved schedule increases the dose every four weeks. Some prescribers accelerate this timeline, which raises the risk of intolerable symptoms. Conversely, clinical data supports extended titration (holding at a lower dose for 8 weeks instead of 4) as a strategy to improve tolerability.

Concurrent medications. Oral contraceptives, certain antibiotics, and other drugs affected by delayed gastric emptying may interact. Dietary factors, particularly high-fat meals, can worsen nausea during the adjustment period.

Individual receptor sensitivity. Genetic variation in GLP-1 receptor expression and signaling affects both efficacy and side-effect intensity. This is an active area of research with no clinical test currently available.

The HealthRX Medical Team's Clinical Framework: Before You Quit a GLP-1

Schumer's decision to stop Mounjaro was hers to make. But her public account highlights a pattern the HealthRX Medical Team sees frequently: patients who discontinue GLP-1 therapy without exhausting tolerability strategies. This is not a criticism of Schumer (we do not know what her prescriber recommended). It is a clinical observation about the broader patient population.

Before discontinuing a GLP-1 agonist for side effects, the HealthRX Medical Team recommends patients discuss these options with their prescriber:

Dose reduction. Dropping back to the previous tolerated dose for an extended period (6 to 8 weeks) before re-attempting escalation. A 5 mg dose that produces 15% weight loss with tolerable symptoms may be preferable to a 15 mg dose that produces 22% loss with vomiting.
Extended titration intervals. The four-week minimum between dose increases is exactly that: a minimum. There is no clinical penalty for taking eight or twelve weeks between steps.
Dietary modification during titration. Smaller, more frequent meals. Reduced fat intake. Avoiding lying down after eating. These are basic gastroparesis management strategies, and they apply directly to GLP-1-induced gastric slowing.
Switching agents within the class. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have different receptor profiles. A patient intolerant to one may tolerate the other. Head-to-head data from SURPASS-2 shows both efficacy and side-effect differences between the two.
Anti-emetic support. Short-term use of ondansetron or other anti-nausea medications during dose escalation is a common clinical strategy, though not formally studied in GLP-1 titration protocols.

What Happens After Stopping: The Discontinuation Reality

The part of Schumer's story that gets less attention is what happens after a patient stops a GLP-1 agonist. The SURMOUNT-4 trial provides the clearest data: participants who switched from tirzepatide to placebo after 36 weeks regained approximately two-thirds of their lost weight over the following 52 weeks. Appetite returned to baseline. Metabolic improvements in HbA1c, blood pressure, and lipids partially reversed.

This is not a failure of willpower. GLP-1 agonists treat obesity as a chronic condition by modifying the hormonal signals that regulate hunger and energy balance. Removing the medication removes those modifications. The comparison is apt: stopping a blood pressure medication does not mean the patient's hypertension was not real.

For patients like Schumer who stop due to side effects, this creates a genuine clinical dilemma. The weight regain trajectory is well-documented, yet continuing an intolerable medication is not a reasonable expectation. The HealthRX Medical Team emphasizes that discontinuation planning should be part of the initial prescribing conversation, not an afterthought.

Postpartum Weight Loss and GLP-1: A Specific Context

Schumer's use of Mounjaro was tied to postpartum weight retention. This context carries specific clinical considerations.

GLP-1 agonists are contraindicated during breastfeeding due to insufficient safety data. The timing of initiation relative to lactation cessation matters. Postpartum hormonal shifts, particularly changes in progesterone, estrogen, and thyroid function, can independently affect gastric motility and nausea sensitivity. A patient who is intolerant to a GLP-1 in the early postpartum period might tolerate it later, once hormonal baselines stabilize.

The HealthRX Medical Team also notes that postpartum weight retention follows a different metabolic pattern than chronic obesity. Some portion of retained weight reflects fluid shifts, muscle mass changes, and hormonal adaptation that resolve over 12 to 18 months without pharmacologic intervention. GLP-1 therapy initiated during this window may be targeting a partially self-correcting condition, which changes the risk-benefit calculation.

What Non-Celebrity Patients Should Take from This

Schumer's public record is valuable precisely because it is incomplete. She confirmed the drug, confirmed the side effects, confirmed stopping. She did not claim the drug was bad or that it does not work. She described a personal outcome.

The clinical takeaways for patients considering or currently taking a GLP-1 agonist:

Side effects are common but usually transient. Most GI symptoms peak during dose escalation and settle within weeks at a stable dose. Stopping during the worst of titration may mean abandoning a medication that would have become tolerable.

Tolerability is not binary. There is a spectrum between "no side effects" and "intolerable." Dose adjustments, dietary changes, and agent switching can shift a patient along that spectrum.

Discontinuation has predictable consequences. Weight regain after stopping a GLP-1 is the expected outcome, not a personal failure. Patients deserve to know this before they start.

Celebrity experiences are anecdotes, not evidence. Schumer's story is a single data point. The SURMOUNT and STEP trial programs enrolled thousands of participants and provide the statistical foundation for clinical decisions.

Frequently asked questions

›